- Home
- HSIC vs QGEN Comparison
HSIC vs QGEN Comparison
Compare HSIC & QGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HSIC
- QGEN
- Stock Information
- Founded
- HSIC 1932
- QGEN 1986
- Country
- HSIC United States
- QGEN Netherlands
- Employees
- HSIC N/A
- QGEN N/A
- Industry
- HSIC Medical Specialities
- QGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HSIC Health Care
- QGEN Health Care
- Exchange
- HSIC Nasdaq
- QGEN Nasdaq
- Market Cap
- HSIC 9.0B
- QGEN 9.1B
- IPO Year
- HSIC 1995
- QGEN 1996
- Fundamental
- Price
- HSIC $73.42
- QGEN $48.08
- Analyst Decision
- HSIC Buy
- QGEN Buy
- Analyst Count
- HSIC 10
- QGEN 8
- Target Price
- HSIC $79.70
- QGEN $50.68
- AVG Volume (30 Days)
- HSIC 1.6M
- QGEN 1.3M
- Earning Date
- HSIC 08-05-2025
- QGEN 08-05-2025
- Dividend Yield
- HSIC N/A
- QGEN 3.14%
- EPS Growth
- HSIC 8.11
- QGEN N/A
- EPS
- HSIC 3.21
- QGEN 0.42
- Revenue
- HSIC $12,669,000,000.00
- QGEN $2,002,874,000.00
- Revenue This Year
- HSIC $4.28
- QGEN $6.36
- Revenue Next Year
- HSIC $3.57
- QGEN $6.18
- P/E Ratio
- HSIC $23.22
- QGEN $115.46
- Revenue Growth
- HSIC 1.75
- QGEN 3.31
- 52 Week Low
- HSIC $60.56
- QGEN $37.63
- 52 Week High
- HSIC $82.49
- QGEN $48.90
- Technical
- Relative Strength Index (RSI)
- HSIC 55.47
- QGEN 59.71
- Support Level
- HSIC $73.02
- QGEN $47.25
- Resistance Level
- HSIC $75.76
- QGEN $48.90
- Average True Range (ATR)
- HSIC 1.36
- QGEN 0.81
- MACD
- HSIC -0.01
- QGEN -0.12
- Stochastic Oscillator
- HSIC 52.24
- QGEN 68.98
About HSIC Henry Schein Inc.
Henry Schein Inc is a solutions company for healthcare professionals powered by a network of people and technology. The company is a provider of healthcare products and services to office-based dental and medical practitioners, as well as alternate sites of care. The company's reportable segments are global Distribution and Value-Added Services; global Specialty Products; and global Technology. It generates the majority of its revenue from the global Distribution and Value-Added Services segment which includes distribution to the global dental and medical markets of national brand and corporate brand merchandise, as well as equipment and related technical services.
About QGEN Qiagen N.V.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2023 sales), followed by EMEA (32%), and the Asia-Pacific (16%).